Astria Therapeutics, Inc.: stockholders equity

What this measure means

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2012-12-31 to 2024-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Astria Therapeutics, Inc.: total assets
• Astria Therapeutics, Inc.: total liabilities
• Astria Therapeutics, Inc.: cash and cash equivalents
• Astria Therapeutics, Inc.: net income or loss
• Astria Therapeutics, Inc.: operating cash flow
• Astria Therapeutics, Inc.: capital expenditure payments
• Astria Therapeutics, Inc.: financing cash flow
• Astria Therapeutics, Inc.: investing cash flow
• Astria Therapeutics, Inc.: retained earnings or deficit
• Astria Therapeutics, Inc.: basic weighted-average shares
• Astria Therapeutics, Inc.: diluted weighted-average shares
• Astria Therapeutics, Inc.: basic earnings per share
• Astria Therapeutics, Inc.: diluted earnings per share
• Astria Therapeutics, Inc.: net property, plant and equipment
• Astria Therapeutics, Inc.: share-based compensation expense
• Astria Therapeutics, Inc.: operating income or loss
• Astria Therapeutics, Inc.: current assets
• Astria Therapeutics, Inc.: interest expense
• Astria Therapeutics, Inc.: current liabilities
• Astria Therapeutics, Inc.: current accounts payable
• Astria Therapeutics, Inc.: operating expenses
• Astria Therapeutics, Inc.: research and development expense
• Astria Therapeutics, Inc.: common shares outstanding
• Astria Therapeutics, Inc.: cash including restricted cash
• Astria Therapeutics, Inc.: additional paid-in capital
• Astria Therapeutics, Inc.: accumulated other comprehensive income or loss
• Astria Therapeutics, Inc.: operating lease right-of-use asset
• Astria Therapeutics, Inc.: operating lease liability
• Astria Therapeutics, Inc.: gross property, plant and equipment
• Astria Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Astria Therapeutics, Inc.: other noncurrent assets
• Astria Therapeutics, Inc.: other noncurrent liabilities
• Astria Therapeutics, Inc.: accrued current liabilities
• Astria Therapeutics, Inc.: prepaid expenses and other current assets
• Astria Therapeutics, Inc.: net deferred tax assets
• Astria Therapeutics, Inc.: profit or loss including noncontrolling interests
• Astria Therapeutics, Inc.: comprehensive income or loss
• Astria Therapeutics, Inc.: net income available to common stockholders
• Astria Therapeutics, Inc.: general and administrative expense
• Astria Therapeutics, Inc.: depreciation, depletion and amortization
• Astria Therapeutics, Inc.: other nonoperating income or expense
• Astria Therapeutics, Inc.: nonoperating income or expense
• Astria Therapeutics, Inc.: interest paid, net
• Astria Therapeutics, Inc.: operating lease payments
• Astria Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Astria Therapeutics, Inc. / CIK 0001454789

Captured

2026-09-21T17:19:11.484Z

SEC response SHA-256

0c1187ffb22e75e74bde771deedbee2b0b16a2d1799abd08a0dda828a5b48a15

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001454789.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))